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 Abstract 
  Background/Aim:  Mutations in  MAPT  cause frontotemporal dementia with parkinsonism linked 
to chromosome 17 (FTDP-17). Patients with the   MAPT   R406W mutation were reported to show 
phenotypic heterogeneity in different ethnic backgrounds. We here report the clinical and ge-
netic characteristics of Japanese families with the R406W mutation.  Methods:  We examined the 
clinical and neuroimaging features of 6 patients from three families with the R406W mutation. 
We determined the genotypes of intragenic  MAPT  single-nucleotide polymorphisms (SNPs) and 
the flanking microsatellite markers to search for a common founder.   Results:   The initial symp-
tom was memory loss with the average age at onset being 54 years. Anterograde amnesia with 
episodic memory impairment was the predominant phenotype. Behavioral and personality 
changes or parkinsonism is not a prominent feature. A brain MRI study revealed marked atrophy 
of the medial temporal lobe. Genetic analysis of SNPs and microsatellite markers revealed that 
the affected members of the three families share common genotypes.   Conclusion:   The find-
ings of the affected members in this study, which corroborate previously reported findings of 
European families, suggest that the R406W mutation may represent a phenotype of predomi-
nant anterograde amnesia in FTLD-17. Our genetic data suggest that a founder effect may ac-
count for some families with the R406W mutation.    Copyright © 2011 S. Karger AG, Basel 
  Published online: September 20, 2011 
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 Introduction 
  Mutations in the microtubule-associated protein tau gene   (MAPT)   cause an inherited 
neurodegenerative disease, i.e. frontotemporal dementia (FTD) with parkinsonism linked to 
chromosome 17 (FTDP-17)   [1]  . More than 100 families with FTLD-17 have been described 
worldwide. It has been demonstrated that phenotypic presentations in patients with FTDP-
17 vary considerably   [2]  . The phenotype of FTDP-17 can be generally divided into two sub-
types: FTD- and parkinsonism-predominant phenotypes   [3]  . Memory impairment occurs 
less frequently as the primary presenting feature, and only in a few cases of FTDP-17, the 
phenotype of predominant memory disturbance is similar to that in Alzheimer’s disease 
(AD)   [4, 5]  .
    The R406W mutation in exon 13 of   MAPT   was previously described in different ethnic 
backgrounds   [6–12]  . The patients with the R406W mutation showed a relatively late onset 
age with an average of 56 years. In the families from Western countries, the patients were 
reported to exhibit a phenotype resembling AD with early memory impairment   [8–10, 12]  . 
In a Dutch family, FTD-like symptoms such as personality changes in addition to initial 
memory impairment were reported   [6]  . Moreover, in a previous study, a Japanese patient 
with the R406W mutation with early disease onset (47 years) and rapidly progressive FTD-
like psychiatric symptoms was reported  [13] . These reports suggest that phenotypic variation 
may also be present in the families with the R406W mutation.
    To further clarify the clinical characteristics of patients with the R406W mutation, we 
here report the clinical and neuroimaging features of three unrelated Japanese families with 
the R406W mutation. We also performed genetic analysis to determine the possibility of a 
common founder in these families.
  M e t h o d s  
 Patients 
 Mutational analysis of two pedigrees with the R406W mutation, Ped 3367 and Ped 3048, 
were previously described  [11, 14] . We found a new family (P4550) with the R406W mutation. 
In this family, the proband’s mother died in her 60s with the clinical diagnosis of AD. The 
family trees are shown in   figure 1  . Although these families all reside in the Niigata Prefec-
ture, Japan, family records revealed no shared surname and no geographical connections; 
thus, they are considered to be apparently unrelated. Six patients from three pedigrees were 
neurologically examined by board-certified neurologists. Six patients were examined by 
brain MRI and 3 by single photon emission computed tomography (SPECT). CSF samples 
were obtained from 2 patients; tau and phosphorylated tau (p181 tau) were quantified using 
a commercially available enzyme immunoassay kit (Innogenetics, Belgium), as previously 
described  [15] . Written informed consent was obtained from all the patients or their caregiv-
ers. This study was approved by the Institutional Review Board of the Niigata University 
School of Medicine.
  Molecular  Genetic  Analysis 
 Genomic DNA was extracted from peripheral blood leukocytes by a standard procedure. 
Mutational analysis was performed by sequencing both strands of all PCR-amplified coding 
exons and flanking intronic sequences of   MAPT ,   APP ,   PSEN1 ,   PSEN2  , and   PRGN  , as previ-
ously reported   [11]  . The   APOE   genotype was determined by restriction enzyme digestion of 
PCR products using   Hha 1.269
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    To determine whether the three families with the R406W mutation share a common 
founder, we determined the genotypes of six single-nucleotide polymorphisms (SNPs) in 
  MAPT   and the six flanking microsatellite markers on chromosome 17q21 in the affected in-
dividuals. Information on SNP genotypes can be retrieved from www.ncbi.nlm.nih.gov/
projects/SNP or http://snp.ims.u-tokyo.ac.jp/. The microsatellite markers spanning   1.3 Mb 
containing the  MAPT  region include D17S930, D17S1861, D17S1804, D17S920, D17S693, and 
D17S1859. The SNP genotypes were determined by direct sequencing of the PCR products 
amplified using appropriate primer pairs. Allele sizes of the microsatellite markers were de-
termined by PCR amplification using fluorescently labeled primers. All the primer sequenc-
es are available on request.
  R e s u l t s  
 Clinical  Characteristics 
  The clinical characteristics of the 6 patients with the R406W mutation are summarized 
in  table 1 . The age at onset of the patients was 54  8  7 years (mean  8  SD; range: 46–68 years). 
These patients commonly showed insidious onset of memory disturbance such as repetition 
of questions and difficulties in remembering appointments and names. Anterograde amne-
sia including a decline in episodic memory was the primarily presenting feature in all pa-
tients, resulting in impairment in ability to work and perform daily activities. The Mini-
Mental State Examination (MMSE) score at a mean disease duration of 10 years was 17   8   6 
(range: 9–25). Behavioral and personality changes were not noted by these patients or their 
caregivers in the early course of the disease. Mild personality changes and disinhibition, such 
as restlessness and garrulousness, were observed in 3 patients with a long duration of the 
disease (Ped 3367-P3; Ped 3048-P2, and Ped 4550-P1). Neurological examination of these 
patients revealed no motor signs of parkinsonism. The clinical diagnosis of early-onset AD 
was suspected in these families prior to genetic investigation.
    Detailed neuropsychological tests were performed on 1 patient (Ped 3367-P1) at the age 
of 56 years, who was alert and cooperative on examination. His speech output was not dis-
turbed, and there were no features of echolalia, verbal stereotype, or perseverations. The 
  Fig. 1.  Pedigrees of families with the  MAPT      R406W 
mutation. Circle = Female; square = male; slash 
through the symbol = deceased individual; black 
symbol = affected individual. 270
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MMSE score was 25/30. Assessment using the Wechsler Adult Intelligence Scale III yielded 
a verbal IQ of 97, a performance IQ of 90, and a full IQ of 93. In the Wechsler Memory Scale-
Revised test, the patient showed low index scores in the delayed recall subtest (score:   ! 50) 
and general memory subtest (score: 65), whereas his index score in the attention/concentra-
tion subtest (score: 98) was normal. His frontal assessment battery score   [16]   was 16/18. The 
clinical assessment of attention consisting of the visual cancellation task, memory updating 
test, paced auditory serial addition test, position Stroop test, and continuous performance 
test   [17]   yielded normal results.
  Molecular  Genetic  Analysis 
  Mutational analysis of   APP ,   PSEN1 ,   PSEN2 ,  MAPT  , and   PGRN   revealed that 6 patients 
from three pedigrees carry a R406W mutation in  MAPT . To examine whether these families 
share a common founder haplotype, we determined the genotypes of intragenic  MAPT  SNPs 
and the flanking microsatellite markers. All the affected individuals from the three ped-
igrees with the R406W mutation shared common genotypes of intragenic   MAPT  SNPs 
(A-C-C-C-A-delT) and the flanking microsatellite markers (105-105-238-100-95-183 at 
D17S930-D17S1861-D17S1804-D17S920-D17S693-D17S1859;   table  2  ). The estimated fre-
quency of the disease-associated haplotype constructed by   MAPT   SNPs and the microsatel-
lite markers (105-105-238-A-C-C-C-A-T-delT-100-95-183) in control subjects from the same 
population was 3.3% (n = 60). All the subjects were homozygous for the H1 haplotype, as 
previously reported   [18]  .
  N e u r o i m a g i n g   F i n d i n g s  
 The brain structure was evaluated by MRI in 6 patients. All the affected subjects showed 
a similar structural change of severe atrophy mainly involving the medial temporal lobe 
(  fig. 2  a–i). Mild cortical atrophy may be observed without apparent hemisphere predomi-
nance. Parenchymal signal changes were absent.
    We investigated regional cerebral blood flow (rCBF) patterns in 3 patients by SPECT. 
The patients in the early stage of the disease did not show a prominent decrease in rCBF. In 
Table 1.   Clinical characteristics of the patients with the MAPT R406W mutation
Ped 3367-P1 Ped 3367-P2 Ped 3367-P3 Ped 3048-P1 Ped 3048-P2 Ped4550-P1
Age at onset, years 51 47 50 56 54 68
Age at examination, years 56 48 67 73 67 77
Duration of disease, years 5 1 17 17 13 9
MMSE score 25 22 9 14 17 16
Dementia stage CDR 1 CDR 0.5 CDR 2 CDR 2 FAST 5 CDR 2
Initial symptom memory loss memory loss memory loss memory loss memory loss memory loss
Memory impairment +++ +++ +++ +++ +++ +++
Personality changes – – + – – +
Disinhibition – – + – + +
Parkinsonism ––––––
CSF tau level, pg/ml 282 116 n/a n/a n/a n/a
CSF p181 tau level, pg/ml 80 74 n/a n/a n/a n/a
APOE typing 3*43 *42 *33 *33 *32 *3
C  DR = Clinical dementia rating scale; FAST = functional assessment stage; n/a = data not available; grading of severity 
of clinical features: – = absent, + = mild, ++ = moderate, +++ = severe.271
Dement Geriatr Cogn Disord Extra 2011;1:267–275
 DOI:  10.1159/000331243 
EXTRA
  Ikeuchi et al.: Japanese Families with the   MAPT  R406W  Mutation 
www.karger.com/dee
  © 2011 S. Karger AG, Basel 
  Published online: September 20, 2011 
the patient with a long disease course of 17 years at the age of 67 years (Ped 3367-P3), the de-
creased rCBF in the bilateral temporal lobes and the cingulate gyrus of the anterior and pos-
terior portions was visualized by   N -isopropyl- p -[ 123 I]iodoamphetamine  ( 123 I-IMP)  SPECT 
using three-dimensional stereotactic surface projection (3D-SSP;   fig. 2  j)   [19]  .
  CSF  Analysis 
  We were able to determine the total and phosphorylated p181 tau levels in the CSF of 2 
patients (Ped 3367-P1 and Ped 3367-P2;   table 1  ). The average total tau level in the patients 
with the R406W mutation is slightly higher than that in our control subjects (157   8   65 pg/
ml, n = 24) and lower than that in patients with AD (555   8   248 pg/ml, n = 31)   [15]  . p181 tau 
was higher than that in the controls (29   8   10 pg/ml, n = 21) and comparable to that in pa-
tients with AD (86   8   39 pg/ml, n = 31).
  Discussion 
  The three families with the   MAPT   R406W mutation presented in this study showed 
relatively uniform clinical characteristics as follows: (1) presenile insidious onset of mem-
ory loss, (2) predominant early clinical features of anterograde amnesia, (3) relatively spare 
behavioral and personality changes or parkinsonism, (4) slow progression of disease, and 
(5) prominent atrophy of the medial temporal lobe involving the hippocampus. These clin-
ical characteristics were similarly observed in Western families with the R406W mutation 
  [8–10, 12]  , suggesting that the predominant symptom of memory impairment with slow-
ly progressive disease may be a cardinal clinical presentation of the R406W mutation ir-
respective of the ethnic background. However, it should be noted that different clinical 
features suggestive of FTD were also observed in a few patients with the R406W mutation 
 [6,  13] .
    The phenotype of prominent memory disturbance was occasionally noted in patients 
with  MAPT  mutations in introns 10 and 16 and P301L  [4, 5, 20] . Similar to our patients, these 
Table 2.   Shared genotypes of MAPT SNPs (in bold) and microsatellite markers in three R406W families
Microsatellite
marker/SNP
Distance from 
MAPTa/location 
in MAPT
Ped 3367
P1
Ped 3367
P2
Ped 3367
P3
Ped 3048
P1
Ped 4550
P1
D17S930 1,147 105 105 105 105 103 105 105 105 105 105
D17S1861 1,063 107 105 103 105 105 105 105 105 103 105
D17S1804 855 238 238 238 238 238 238 238 238 236 238
rs242557 intron 1 G A G A G A G A G A
rs63750222 exon 4A C C C C C C C C C C
rs2258689 exon 6 T C T C T C T C C C
rs2435211 intron 6 T C T C C C T C C C
rs2435200 intron 9 G A G A G A G A A A
pR406W exon 12 C T C T C T C T C T
rs5820605 exon 14 T – T – – – T – – –
D17S920 423 100 100 100 100 102 100 102 100 102 100
D17S693 575 99 95 95 95 99 95 99 95 95 95
D17S1859 1,425 181 183 177 183 177 183 181 183 177 183
a Distance from MAPT (in kb) was calculated on the basis of the latest human assembly GRCh37.p2 
(www.ncbi.nlm.nih.gov/projects/genome/assembly/grc/human/index.shtml).272
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patients were misdiagnosed as having AD prior to genetic or pathological analysis. Promi-
nent early memory impairment is characteristic of AD and is an exclusion criterion for the 
diagnosis of FTD   [21]  . It remains unclear how some   MAPT   mutations lead to the phenotype 
of memory disturbance reminiscent of AD. In the case of R406W families, this phenotype 
may be explained by the prominent involvement of the hippocampus, which is considered 
the pathological substrate for memory impairment. Indeed, in the R406W patients in this 
study severe atrophy was noted in the hippocampus on MR images (  fig. 2  ). This notion is 
supported by previous neuropathological studies showing that neuronal loss and gliosis are 
observed together with tau-positive neurofibrillary tangles and neuronal threads in the me-
dial temporal lobe including the hippocampi   [6, 7, 12, 13, 22]  .
    Genetic analysis of the intragenic   MAPT   SNPs and the flanking microsatellite markers 
demonstrated that the three families with the R406W mutation in this study shared the same 
genotypes. This finding raises the intriguing notion that they may share extended chromo-
somal segments around the tau locus and have a common founder among their ancestors 
even though they are apparently unrelated pedigrees. This notion is supported by the obser-
vation that the frequency of the disease-associated haplotype in the general population is as 
low as 3.3%. The similarity of the phenotype observed in our families may be explained by 
the possibility that these families may represent a single extended R406W pedigree. In con-
trast to our findings, three families from Western Europe have been reported to carry dif-
ferent haplotypes among families   [8]  , arguing against the founder effect; thus, the R406W 
mutation in these families seems to arise independently. Taken together, although the found-
er effect of the R406W mutation is responsible for the occurrence in some families, the same 
mutation may also occur independently in different kindreds.
    In conclusion, findings on our and previously described cases suggest that the R406W 
mutation occurs pan-ethnically and may represent a peculiar phenotype of predominant 
anterograde amnesia of FTDP-17 in addition to two well-known core phenotypes of FTDP-
17: the FTD- and parkinsonism-predominant phenotypes. Because anterograde amnesia is 
the prototypical presentation of AD, using solely the clinical diagnostic criteria in the fami-
lies with the R406W mutation failed to properly identify the pathological substrate of their 
disease. A similar AD-like phenotype exhibiting anterograde amnesia was reported in a 
family with a mutation (c.154delA) in   PGRN     [23]  , another causative gene for FTLD. On the 
other hand, some   PSEN1   mutations responsible for early-onset familial AD may cause the 
FTD-like phenotype  [24, 25] . Comprehensive mutational analysis of genes including  PSEN1 , 
  PSEN2 ,  APP ,  MAPT , and  PGRN  would be necessary for familial dementia with a broad spec-
trum of overlapping clinical phenotypes.
  Fig. 2.   Representative T  1  -weighted MR images of 3 patients: Ped 3367-P1 at the age of 56 years (  a–c );  Ped 
3367-P3 at the age of 67 years (  d–f  ), and Ped 4550-P1 at the age of 77 years (  g–i  ). Coronal images revealed 
marked atrophy of the medial temporal lobe including the hippocampus and parahypocampal gyrus (  a ,   d , 
  e ). On axial images, an enlarged inferior horn of the lateral ventricles was observed ( b ,  e ,  h ). Atrophic change 
in the frontal lobe is less noticeable (  c ,   f ,   i ).   j   Decreased rCBF by   123  I-IMP SPECT with 3D-SSP in Ped 3367-
P3 at the age of 67 years. After global normalization to the mean blood flow for the entire brain, rCBF in 
the patient was compared with that in normal controls by the Z test. Color-coding represents the statistical 
significance (Z score) of the decrease in rCBF. Decreases in rCBF were observed in the bilateral temporal 
lobes as well as in the cingulate gyrus of anterior (ANT) and posterior (POST) portions. L = Left; R = right; 
INF = inferior; LAT = lateral; MED = medial; SUP = superior. 274
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